浩欧博收盘上涨2.86%，滚动市盈率228.78倍，总市值79.24亿元

Core Viewpoint - Jiangsu Haobio's stock closed at 124.82 yuan, with a PE ratio of 228.78 times, significantly higher than the industry average of 55.46 times, indicating potential overvaluation in the market [1][3] Company Overview - Jiangsu Haobio specializes in the research, production, and sales of in vitro diagnostic reagents, with key products including allergy and autoimmune reagents [2] - The company holds 226 product registration certificates and 57 patents, and has received multiple honors, including being recognized as a high-tech enterprise and a "national specialized and innovative 'little giant' enterprise" [2] Financial Performance - For Q1 2025, the company reported revenue of 77.61 million yuan, a year-on-year decrease of 9.33%, and a net profit of 1.64 million yuan, down 56.97% from the previous year, with a gross margin of 57.98% [2] Market Position - The company's market capitalization stands at 7.924 billion yuan, ranking 114th in the medical device industry based on PE ratio, which is significantly higher than the industry median of 37.74 times [1][3]